Deal volume fell by 24 per cent to its lowest level since mid-2020, despite predictions of a surge in activity in the wake of ...

A ctDNA-guided approach can help identify when patients with HR-positive advanced breast cancer are developing an ESR1 ...

Upfront surgery for advanced ovarian cancer failed to improve overall survival (OS) versus interval debulking but did improve ...

Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 2:00 p.m. ET.

Neglected tropical diseases (NTDs) are a diverse group of conditions1 that still affect 1 billion people, mainly vulnerable populations in underserved ...

GlaxoSmithKline (GSK – Research Report) received a Hold rating and a $41.00 price target from Berenberg Bank analyst Kerry Holford today. Confident Investing Starts Here: Easily ...

Among patients who received four-drug consolidation therapy, 84% had measurable residual disease (MRD)-negative status before ...

CHICAGO -- A single infusion of the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel (cilta-cel; ...

The biotech’s mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to ...

These mutated diseases defy the power of antibiotics. Are illnesses really mutating so fast that we can’t stay ahead of them?

There have been important recent advances in the management of Crohn's disease, including new classes of biological or small molecule therapies, an appreciation that endoscopic mucosal healing results ...

Take a closer look at London's biotech hub – renowned for its thriving life sciences ecosystem and world-class infrastructure ...